Campbell Rogers Sells 9,219 Shares of Heartflow (NASDAQ:HTFL) Stock

Heartflow, Inc. (NASDAQ:HTFL) insider Campbell Rogers sold 9,219 shares of the firm’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $28.34, for a total transaction of $261,266.46. Following the completion of the transaction, the insider directly owned 78,731 shares in the company, valued at approximately $2,231,236.54. This represents a 10.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Campbell Rogers also recently made the following trade(s):

• On Wednesday, April 1st, Campbell Rogers sold 64,533 shares of Heartflow stock. The shares were sold at an average price of $24.64, for a total transaction of $1,590,093.12.
• On Thursday, March 19th, Campbell Rogers sold 64,533 shares of Heartflow stock. The shares were sold at an average price of $25.69, for a total transaction of $1,657,852.77.

Heartflow Trading Up 6.6%

Shares of Heartflow stock opened at $29.20 on Friday. The firm has a market capitalization of $2.52 billion and a PE ratio of -9.39. The firm’s 50 day moving average is $27.58 and its 200 day moving average is $28.51. Heartflow, Inc. has a 1 year low of $20.13 and a 1 year high of $41.22.

Heartflow (NASDAQ:HTFL) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.08. The company had revenue of $52.59 million for the quarter. The business’s revenue for the quarter was up 41.3% compared to the same quarter last year. As a group, research analysts anticipate that Heartflow, Inc. will post -0.78 earnings per share for the current year.

Institutional Investors Weigh In On Heartflow

Hedge funds have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd acquired a new stake in Heartflow during the 4th quarter worth approximately $27,000. Russell Investments Group Ltd. acquired a new stake in Heartflow during the 4th quarter worth approximately $45,000. Essential Partners LLC acquired a new stake in Heartflow during the 1st quarter worth approximately $57,000. Legal & General Group Plc acquired a new stake in Heartflow during the 3rd quarter worth approximately $59,000. Finally, Strs Ohio acquired a new stake in Heartflow during the 4th quarter worth approximately $99,000.

Analysts Set New Price Targets

HTFL has been the topic of several research reports. JPMorgan Chase & Co. decreased their price target on shares of Heartflow from $40.00 to $35.00 and set an “overweight” rating on the stock in a report on Thursday, March 19th. Canaccord Genuity Group decreased their price target on shares of Heartflow from $43.00 to $37.00 and set a “buy” rating on the stock in a report on Friday, May 15th. William Blair initiated coverage on shares of Heartflow in a report on Monday, May 4th. They set an “outperform” rating on the stock. Finally, Wells Fargo & Company lifted their price target on shares of Heartflow from $35.00 to $37.00 and gave the company an “overweight” rating in a report on Friday, May 15th. Six investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Heartflow has an average rating of “Moderate Buy” and an average price target of $37.00.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.